Anti-Vaginolysin [23A2]

Absolute Antibody

Anti-Vaginolysin [23A2]

7

The antibody binds to VLY with an affinity (Kd) of 0.12 nM and an IC50 of 0.48 nM (determined by hemolytic assay). The antibody has a fair neutralizing capability.

The antibody binds specifically to VLY, a pore-forming toxic member of the cholesterol-dependent cytolysins, produced by the bacterium Gardnerella vaginalis. Once released, VLY acts by binding to cholesterol-rich membranes and forming transmembrane pores that result in lysis of the cell. The bacterium G. vaginalis is predominant in the vaginal tract of women with bacterial vaginosis (BV). Here releases VLY toxins that cause cytolysis and tissue destruction, and potentially leading to serious adverse effects such as infertility. Antibodies that are able to neutralize the toxic activity of VLY can be used as therapeutic agents for the treatment of BV.

Western Blot, ELISA, Neutralisation/Blocking

ELISA; WB; Block

Research Use Only

Monoclonal

23A2

Mouse

IgG1

Bacteria

G. vaginalis

Recombinant VLY.

-20°C,2°C to 8°C

12352203